Universal Ibogaine Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Universal Ibogaine.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Healthcare earnings growth23.1%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

None

Last updatedn/a

Recent future growth updates

Recent updates

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Universal Ibogaine has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.

Earnings and Revenue Growth Forecasts

DB:JC4 - Analysts future estimates and past financials data (CAD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
4/30/20242-2-1-1N/A
1/31/20242-1-10N/A
10/31/20232-2-1-1N/A
7/31/20231-2-1-1N/A
4/30/20231-6-3-3N/A
1/31/20231-7-4-3N/A
10/31/20221-7-4-4N/A
7/31/20221-10-4-4N/A
4/30/20221-8-4-4N/A
1/31/20221-8-4-4N/A
10/31/20210-7-4-4N/A
7/31/2021N/A-4-3-3N/A
4/30/2021N/A-6-4-4N/A
7/31/2020N/A-6-2-2N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if JC4's forecast earnings growth is above the savings rate (0.8%).

Earnings vs Market: Insufficient data to determine if JC4's earnings are forecast to grow faster than the German market

High Growth Earnings: Insufficient data to determine if JC4's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if JC4's revenue is forecast to grow faster than the German market.

High Growth Revenue: Insufficient data to determine if JC4's revenue is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if JC4's Return on Equity is forecast to be high in 3 years time


Discover growth companies